Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (4113)	2/18/1998 4:55:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

squetch, I got a copy of the full paper and you appear to be correct. Quoting selectively: "One of the major differences in the biodistribution of the RNases is found in kidney uptake and retention. The amount of onconase detected in the kidneys is higher than for other RNases, ranging from a 2-4-fold difference at 15 min to a 50-100-fold difference at 180 min. Because kidney toxicity was found to be dose-limiting in clinical trials of onconase (cite paper with phase I data), an understanding of the mechanism for this unusually high retention in the kidney has important clinical implications." Thus, this issue has been known since the phase I study, published in 1993. And this paper (Cancer Research 1996) attempts to understand the effect at a more molecular level. The good news for Alfacell seems to be that, with the results of the paper, it may be possible to redesign onconase as to make it less likely to be retained in the kidney, and therefore improve its therapeutic index ... at least in BALB/c mice. Pseudo Pharmacologist